James Harry Hull

James Harry Hull

Auto-generated profile, based on publicly available information

James Harry Hull

Institute of Sport, Exercise and Health, University College London, London, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in British Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
MWMathew G Wilson
Mathew G Wilson
JHJames H Hull
James H Hull
JRJohn Rogers
John Rogers
NPNoel Pollock
Noel Pollock
MDMiranda Dodd
Miranda Dodd
SSSanjay Sharma
Sanjay Sharma
SARS-CoV-2 is the causative virus responsible for the COVID-19 pandemic. This pandemic has necessitated that all professional and elite sport is either suspended, postponed or cancelled altogether to minimise the risk of viral spread. As infection rates drop and quarantine restrictions are lifted, the question how athletes can safely resume competitive sport is being asked. Given the rapidly evolving knowledge base about the virus and changing governmental and public health recommendations, a precise answer to this question is fraught with complexity and nuance. Without robust data to inform policy, return-to-play (RTP) decisions are especially difficult for elite athletes on the suspicion that the COVID-19 virus could result in significant cardiorespiratory compromise in a minority of afflicted athletes. There are now consistent reports of athletes reporting persistent and residual symptoms many weeks to months after initial COVID-19 infection. These symptoms include cough, tachycardia and extreme fatigue. To support safe RTP, we provide sport and exercise medicine physicians with practical recommendations on how to exclude cardiorespiratory complications of COVID-19 in elite athletes who place high demand on their cardiorespiratory system. As new evidence emerges, guidance for a safe RTP should be updated.

1 June 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
JHJames H Hull
James H Hull
MLMike Loosemore
Mike Loosemore
MSMartin Schwellnus
Martin Schwellnus

1 November 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JHJames H. Hull
James H. Hull
VBVibeke Backer
Vibeke Backer
PGpeter gibson
peter gibson
SFStephen J. Fowler
Stephen J. Fowler
The larynx is one of the most highly innervated organs in humans and serves a number of vitally important, complex, and highly evolved biological functions. On a day-to-day basis, the larynx functions autonomously, addressing several roles including airway protection, swallowing, and phonation. In some situations the larynx appears to adopt a functional state that could be considered maladaptive or “dysfunctional.” This laryngeal dysfunction can underpin and account for a number of respiratory symptoms that otherwise appear incongruous with a clinical disease state and/or contribute to the development of symptoms that appear “refractory” to treatment. These include conditions associated with a heightened tendency for inappropriate laryngeal closure (e.g., inducible laryngeal obstruction), voice disturbance, and chronic cough. Recognition of laryngeal dysfunction is important to deliver targeted treatment and failure to recognize the condition can lead to repeated use of inappropriate treatment. Diagnosis is not straightforward, however, and many patients appear to present with symptoms attributable to laryngeal dysfunction, but in whom the diagnosis has been overlooked in clinical work-up for some time. This review provides an overview of the current state of knowledge in the field of laryngeal dysfunction, with a focus on pragmatic clinical assessment and management.

14 September 2017 in Respirology
Verified
Journal Article
Closed access
PDF file
STSarah Todd
Sarah Todd
EWEmil S. Walsted
Emil S. Walsted
LGLizzie Grillo
Lizzie Grillo
RLRebecca Livingston
Rebecca Livingston
AMAndrew Menzies‐Gow
Andrew Menzies‐Gow
JHJames H. Hull
James H. Hull

2 August 2021 in British Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
JHJames H Hull
James H Hull
MWMoses Wootten
Moses Wootten
MMMoiz Moghal
Moiz Moghal
NHNeil Heron
Neil Heron
RMRhodri Martin
Rhodri Martin
CRCraig Ranson
Craig Ranson
Objectives To report COVID-19 illness pattern, symptom duration and time loss in UK elite athletes. Methods Observational, clinical and database review of athletes with symptomatic COVID-19 illness managed within the UK Sports Institutes. Athletes were classified as confirmed (positive SARS-CoV-2 PCR or antibody tests) or probable (consistent clinical features) COVID-19. Clinical presentation was characterised by the predominant symptom focus (eg, upper or lower respiratory illness). Time loss was defined as days unavailable for full sport participation and comparison was made with a 2016–2019 respiratory illness dataset from the same surveillance system. Results Between 24 February 2020 and 18 January 2021, 147 athletes (25 Paralympic (17%)) with mean (SD) age 24.7 (5.2) years, 37% female, were diagnosed with COVID-19 (76 probable, 71 confirmed). Fatigue was the most prevalent symptom (57%), followed by dry cough (50%) and headache (46%). The median (IQR) symptom duration was 10 (6–17) days but 14% reported symptoms >28 days. Median time loss was 18 (12–30) days, with 27% not fully available >28 days from initial date of infection. This was greater than our historical non-COVID respiratory illness comparator; 6 days, 0–7 days (p<0.001) and 4% unavailable at 28 days. A lower respiratory phenotype (ie, including dyspnoea±chest pain±cough±fever) was present in 18% and associated with a higher relative risk of prolonged symptoms risk ratio 3.0 (95% CI: 1.4 to 6.5) and time loss 2.1 (95% CI: 1.2 to 3.5). Conclusions In this cohort, COVID-19 largely resulted in a mild, self-limiting illness. The presence of lower respiratory tract features was associated with prolonged illness and a delayed return to sport.

22 February 2022 in British Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
HCHege Havstad Clemm
Hege Havstad Clemm
JOJ Tod Olin
J Tod Olin
CMCameron McIntosh
Cameron McIntosh
MSMartin Schwellnus
Martin Schwellnus
NSNicola Sewry
Nicola Sewry
THThomas Halvorsen
Thomas Halvorsen
Exercise-induced laryngeal obstruction (EILO) is caused by paradoxical inspiratory adduction of laryngeal structures during exercise. EILO is an important cause of upper airway dysfunction in young individuals and athletes, can impair exercise performance and mimic lower airway dysfunction, such as asthma and/or exercise-induced bronchoconstriction. Over the past two decades, there has been considerable progress in the recognition and assessment of EILO in sports medicine. EILO is a highly prevalent cause of unexplained dyspnoea and wheeze in athletes. The preferred diagnostic approach is continuous visualisation of the larynx (via laryngoscopy) during high-intensity exercise. Recent data suggest that EILO consists of different subtypes, possibly caused via different mechanisms. Several therapeutic interventions for EILO are now in widespread use, but to date, no randomised clinical trials have been performed to assess their efficacy or inform robust management strategies. The aim of this review is to provide a state-of-the-art overview of EILO and guidance for clinicians evaluating and treating suspected cases of EILO in athletes. Specifically, this review examines the pathophysiology of EILO, outlines a diagnostic approach and presents current therapeutic algorithms. The key unmet needs and future priorities for research in this area are also covered.